Shock, Septic Clinical Trial
Official title:
Pituitary Function After Recovery From Septic Shock Among ICU Survivors: A Prospective, Observational Study
Prolonged circulatory shock is associated with marked disturbances in vascular supply to the brain, and endothelial dysfunction which can lead to disseminated intravascular coagulation and microvascular thrombosis. Pituitary dysfunction is documented following post-partum hemorrhage, traumatic brain injury and subarachnoid hemorrhage, which also affect blood flow to the pituitary. However, there are no studies assessing pituitary function in the aftermath of recovery from shock. This will be a prospective observational study of patients admitted in Critical Care Medicine (CCM) ICU who have recovered from prolonged septic shock (Lasting for a period of > 24 hours). Blood samples of the participants will be estimated at the time of discharge from the ICU and at 6 months post discharge. Investigators will estimate fasting serum cortisol, TSH, Free T4, Testosterone (in males), Oestrogen (in females), LH, FSH, Prolactin, IGF-1 and plasma ACTH in all participants at both time points (at the time of ICU discharge and at 6-months follow-up). Participants who have borderline serum cortisol values (138-400 nmol/l) will be subjected to 250ug ACTH stimulation test. Expected outcome of the proposed study is to know proportion of patients having pituitary hormone axis dysfunction. Investigators will also look for pituitary dysfunction persist or revert, or there are new onset dysfunction at 6 month follow up. This would have major implications in the follow up and management of ICU survivors.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | August 2025 |
Est. primary completion date | August 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients 18-80 years of age who meet the definition of septic shock. - Vasopressor requirement should be maintained for a period > 24 hours and should require ICU stay for a duration of > 7 days. - Patient should recover from shock and be planned for discharge from the ICU. Exclusion Criteria: - Patients who refuse to provide consent. - Age <18 years or > 80 years of age. - Pregnancy or immediate post-partum (< 6 months post-delivery). - Chronic kidney disease (Stage 5), chronic liver disease (CHILD B or C), severe Chronic obstructive pulmonary disease, Chronic heart failure. - Patients with pre-existing hypopituitarism on replacement. - Past history of severe post-partum hemorrhage requiring blood transfusion, traumatic brain injury, subarachnoid hemorrhage, pituitary tumor/surgery, snake bite envenomation and meningo-encephalitis. - Patients who have been on > 5 mg prednisolone equivalent for a period of more than 2 weeks at any time in the previous 6 months before admission. |
Country | Name | City | State |
---|---|---|---|
India | Department of Critical Care Medicine, SGPGIMS | Lucknow | UP |
India | Department of Endocrinology, SGPGIMS | Lucknow | Uttar Pradesh |
Lead Sponsor | Collaborator |
---|---|
Sanjay Gandhi Postgraduate Institute of Medical Sciences |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pituitary dysfunction at discharge | Frequency of dysfunction of various hypothalamo-pituitary hormone axes | Immediately before the ICU discharge | |
Secondary | Pituitary dysfunction at 6 months | Frequency of dysfunction of various hypothalamo-pituitary hormone axes on follow up | Six months after the ICU discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03592693 -
Vitamin C, Hydrocortisone and Thiamine for Septic Shock
|
Phase 2 | |
Terminated |
NCT01639664 -
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
|
N/A | |
Withdrawn |
NCT01601938 -
Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients
|
Phase 2 | |
Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
Completed |
NCT00000574 -
Ibuprofen in Sepsis Study
|
Phase 3 | |
Recruiting |
NCT04910841 -
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
|
N/A | |
Active, not recruiting |
NCT04079829 -
Postoperative Respiratory Abnormalities
|
||
Recruiting |
NCT04569942 -
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
|
Phase 3 | |
Recruiting |
NCT04934943 -
"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
|
||
Completed |
NCT01310790 -
Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock
|
Phase 4 | |
Completed |
NCT00241228 -
Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)
|
N/A | |
Completed |
NCT00046072 -
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
|
Phase 2 | |
Withdrawn |
NCT03122678 -
Thiamine Supplementation in Patients With Septic Shock
|
Phase 1 | |
Recruiting |
NCT06155812 -
Multimodal Vasopressor Strategy in Septic Shock
|
Phase 2/Phase 3 | |
Completed |
NCT04178148 -
Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock
|
N/A | |
Completed |
NCT01453270 -
Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial
|
N/A | |
Completed |
NCT04576819 -
Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
|
||
Active, not recruiting |
NCT04055909 -
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
|
Phase 2 | |
Suspended |
NCT03193164 -
Neuromuscular Electrical Stimulation and Septic Shock
|
N/A | |
Completed |
NCT04647552 -
Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock
|